亨迪药业(301211.SZ)：非布司他片获药品注册证书

Core Viewpoint - The company, Hendi Pharmaceutical (301211.SZ), has received approval from the National Medical Products Administration for the registration certificate of Febuxostat tablets, which are used for the long-term treatment of hyperuricemia and gout patients [1] Group 1 - The approved drug, Febuxostat tablets, is a xanthine oxidase inhibitor [1] - The primary indication for Febuxostat tablets is the long-term treatment of hyperuricemia and gout, including the management of uric acid levels after acute attacks of gouty arthritis [1]